ABSTRACT
Hyperglycaemia is commonly observed on admission and during hospitalization for medical illness, traumatic injury, burn and surgical intervention. This transient hyperglycaemia is referred to as stress-induced hyperglycaemia (SIH) and frequently occurs in individuals without a history of diabetes. SIH has many of the same underlying hormonal disturbances as diabetes mellitus, specifically absolute or relative insulin deficiency and glucagon excess. SIH has the added features of elevated blood levels of catecholamines and cortisol, which are not typically present in people with diabetes who are not acutely ill. The seriousness of SIH is highlighted by its greater morbidity and mortality rates compared with those of hospitalized patients with normal glucose levels, and this increased risk is particularly high in those without pre-existing diabetes. Insulin is the treatment standard for SIH, but new therapies that reduce glucose variability and hypoglycaemia are desired. In the present review, we focus on the key role of glucagon in SIH and discuss the potential use of glucagon receptor blockers and glucagon-like peptide-1 receptor agonists in SIH to achieve target glucose control.
Subject(s)
Glucagon/physiology , Hyperglycemia/etiology , Stress, Physiological/physiology , Diabetes Mellitus, Type 1/physiopathology , Diabetes Mellitus, Type 2/physiopathology , Glucagon/metabolism , Glucagon-Like Peptide-1 Receptor/agonists , Glucagon-Like Peptide-1 Receptor/antagonists & inhibitors , Humans , Hyperglycemia/drug therapy , Hyperglycemia/physiopathologyABSTRACT
Hypoglycemic sulfonylureas represent a group of clinically useful antidiabetic compounds that stimulate insulin secretion from pancreatic beta cells. The molecular mechanisms involved are not fully understood but are believed to involve inhibition of potassium channels sensitive to adenosine triphosphate (KATP channels) in the beta cell membrane, causing membrane depolarization, calcium influx, and activation of the secretory machinery. In addition to these effects, sulfonylureas also promoted exocytosis by direct interaction with the secretory machinery not involving closure of the plasma membrane KATP channels. This effect was dependent on protein kinase C (PKC) and was observed at therapeutic concentrations of sulfonylureas, which suggests that it contributes to their hypoglycemic action in diabetics.
Subject(s)
Exocytosis/drug effects , Hypoglycemic Agents/pharmacology , Islets of Langerhans/physiology , Protein Kinase C/metabolism , Sulfonylurea Compounds/pharmacology , Tolbutamide/pharmacology , Animals , Calcium/metabolism , Cells, Cultured , Cytoplasmic Granules/metabolism , Electric Conductivity , Glipizide/pharmacology , Glyburide/pharmacology , Insulin/metabolism , Insulin Secretion , Islets of Langerhans/drug effects , Membrane Potentials/drug effects , Mice , Patch-Clamp TechniquesABSTRACT
Mice, deficient for vascular endothelial growth factor VEGF-A in pancreatic islets, have reduced insulin gene expression levels and an impaired glucose tolerance. Here, we investigated whether VEGF-A was required for physiological glucose-stimulated insulin secretion and insulin content. We performed in situ pancreas perfusions and islet perifusions on mice lacking VEGF-A in the pancreatic epithelium in order to study their ability to secrete insulin in response to glucose. We identified insulin secretion defects in the pancreata of VEGF-A deficient mice, including a delayed and blunted response to glucose. Islet perifusion experiments revealed a missing first phase and weaker second phase of insulin secretion, in two of three VEGF-A deficient mice. On average, insulin content in VEGF-A deficient islets was significantly reduced when compared with control islets. We conclude that VEGF-A is required in pancreatic islets for normal glucose-stimulated insulin secretion and physiological insulin content. Thus, VEGF-A is a key factor for pancreatic islet function.
Subject(s)
Insulin/metabolism , Islets of Langerhans/metabolism , Vascular Endothelial Growth Factor A/genetics , Animals , Arginine/pharmacology , Cells, Cultured , Down-Regulation/drug effects , Glucose/pharmacology , Insulin Secretion , Islets of Langerhans/drug effects , Islets of Langerhans/physiology , Mice , Mice, Knockout , Time Factors , Vascular Endothelial Growth Factor A/metabolismABSTRACT
AIM: Muscle wasting is one of the factors most strongly predicting mortality and morbidity in critically ill intensive care unit (ICU). This muscle wasting affects both limb and respiratory muscles, but the understanding of underlying mechanisms and muscle-specific differences remains incomplete. This study aimed at investigating the temporal expression and phosphorylation of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway in muscle wasting associated with the ICU condition to characterize the JAK/STAT proteins and the related changes leading or responding to their activation during exposure to the ICU condition. METHODS: A novel experimental ICU model allowing long-term exposure to the ICU condition, immobilization and mechanical ventilation, was used in this study. Rats were pharmacologically paralysed by post-synaptic neuromuscular blockade and mechanically ventilated for durations varying between 6 hours and 14 days to study muscle-specific differences in the temporal activation of the JAK/STAT pathway in plantaris, intercostal and diaphragm muscles. RESULTS: The JAK2/STAT3 pathway was significantly activated irrespective of muscle, but muscle-specific differences were observed in the temporal activation pattern between plantaris, intercostal and diaphragm muscles. CONCLUSION: The JAK2/STAT3 pathway was differentially activated in plantaris, intercostal and diaphragm muscles in response to the ICU condition. Thus, JAK2/STAT3 inhibitors may provide an attractive pharmacological intervention strategy in immobilized ICU patients, but further experimental studies are required in the study of muscle-specific effects on muscle mass and function in response to both short- and long-term exposure to the ICU condition prior to the translation into clinical research and practice.
Subject(s)
Janus Kinase 2/metabolism , Muscle, Skeletal/metabolism , Respiration, Artificial/adverse effects , Restraint, Physical/adverse effects , STAT3 Transcription Factor/metabolism , Animals , Female , Muscle, Skeletal/pathology , Muscular Atrophy/etiology , Muscular Atrophy/metabolism , Phosphorylation , Rats , Rats, Sprague-DawleyABSTRACT
Effects of membrane potential and cytosolic free Ca2+ concentrations ([Ca2+]i) on acetycholine (ACh)-induced inositol phosphate production were investigated in insulin secreting betaTC3 cells. ACh (10 microM) caused a rapid inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) production and increase in [Ca2+]i reaching a maximum within 5 s. The rise in Ins(1,4,5)P3 production was reduced by 79 +/- 5% when [Ca2+]i was kept low in cells loaded with the Ca2+ chelator BAPTA. The ACh-evoked Ins(1,4,5)P3 production also depended on the membrane potential as it was reduced by 31 +/- 6% in cells hyperpolarized by diazoxide, an opener of ATP-sensitive K+ channels. The Ca2+ ionophore ionomycin caused a rapid increase in [Ca2+]i and in the cellular Ins(1,4,5)P3 content. We conclude that stimulation-induced changes in membrane potential and [Ca2+]i play an important role in controlling Ins(1,4,5)P3 production in insulin-secreting betaTC3 cells.
Subject(s)
Acetylcholine/pharmacology , Calcium/metabolism , Cytosol/metabolism , Inositol 1,4,5-Trisphosphate/biosynthesis , Insulin/metabolism , Animals , Cell Line , Egtazic Acid/analogs & derivatives , Enzyme Activation , Ionomycin/pharmacology , Membrane Potentials , Mice , Receptors, Muscarinic/drug effects , Time Factors , Type C Phospholipases/metabolismABSTRACT
The mechanisms by which glucose-dependent insulinotropic polypeptide (GIP) stimulates insulin secretion were investigated by measurements of whole-cell Ca2+ currents, the cytoplasmic Ca2+ concentration, and cell capacitance as an indicator of exocytosis in individual mouse pancreatic beta-cells maintained in short-term culture. GIP produced a 4.2-fold potentiation of depolarization-induced exocytosis. This stimulation of exocytosis was not associated with a change in the whole-cell Ca2+-current, and there was only a small increase (30%) in the cytoplasmic Ca2+ concentration [intercellular free Ca2+([Ca2+]i)]. The stimulatory effect of GIP on exocytosis was blocked by pretreatment with the specific protein kinase A (PKA) inhibitor Rp-8-Br-cAMPS. Glucagon-like peptide-I(7-36) amide (GLP-I) stimulated exocytosis (90%) in the presence of a maximal GIP concentration (100 nmol/l). Replacement of GLP-I with forskolin produced a similar stimulatory action on exocytosis. These effects of GLP-I and forskolin in the presence of GIP did not involve a change in the whole-cell Ca2+-current or [Ca2+]i. GIP was ineffective in the presence of both forskolin and the phosphodiesterase inhibitor isobutylmethylxanthine (IBMX). Under the same experimental conditions, the protein kinase C (PKC)-activating phorbol ester 4-phorbol 12-myristate 13-acetate (PMA) stimulated exocytosis (60%). Collectively, our data indicate that the insulinotropic hormone GIP stimulates insulin secretion from pancreatic beta-cells, through the cAMP/PKA signaling pathway, by interacting with the secretory machinery at a level distal to an elevation in [Ca2+]i.
Subject(s)
Cyclic AMP-Dependent Protein Kinases/physiology , Exocytosis/physiology , Gastric Inhibitory Polypeptide/pharmacology , Islets of Langerhans/physiology , 1-Methyl-3-isobutylxanthine/pharmacology , Animals , Calcium/physiology , Cell Membrane/drug effects , Cell Membrane/physiology , Cells, Cultured , Colforsin/pharmacology , Cyclic AMP/analogs & derivatives , Cyclic AMP/pharmacology , Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors , Cyclic AMP-Dependent Protein Kinases/drug effects , Dose-Response Relationship, Drug , Electric Conductivity , Enzyme Inhibitors/pharmacology , Exocytosis/drug effects , Gastrointestinal Hormones/pharmacology , Glucagon/pharmacology , Glucagon-Like Peptide 1 , Glucagon-Like Peptides , Islets of Langerhans/cytology , Islets of Langerhans/drug effects , Membrane Potentials/drug effects , Membrane Potentials/physiology , Mice , Mice, Inbred Strains , Peptide Fragments/pharmacology , Phosphodiesterase Inhibitors/pharmacology , Tetradecanoylphorbol Acetate/pharmacology , Thionucleotides/pharmacologyABSTRACT
High-resolution capacitance measurements were used to explore the effects of the gut hormones GLP-I(7-36) amide [glucagon-like peptide I(7-36) amide] and GIP (glucose-dependent insulinotropic polypeptide) on Ca2+-dependent exocytosis in glucagon-secreting rat pancreatic alpha-cells. Both peptides produced a greater than threefold potentiation of secretion evoked by voltage-clamp depolarizations, an effect that was associated with an approximately 35% increase of the Ca2+ current. The stimulatory actions of GLP-I(7-36) amide and GIP were mimicked by forskolin and antagonized by the protein kinase A (PKA)-inhibitor Rp-8-Br-cAMPS. The islet hormone somatostatin inhibited the stimulatory action of GLP-I(7-36) amide and GIP via a cyclic AMP-independent mechanism, whereas insulin had no effect on exocytosis. These data suggest that the alpha-cells are equipped with receptors for GLP-I and GIP and that these peptides, in addition to their well-established insulinotropic capacity, also stimulate glucagon secretion. We propose that the reported inhibitory action of GLP-I on glucagon secretion is accounted for by a paracrine mechanism (e.g., mediated by stimulated release of somatostatin that in turn suppresses exocytosis in the alpha-cell).
Subject(s)
Calcium/pharmacology , Cyclic AMP-Dependent Protein Kinases/physiology , Gastric Inhibitory Polypeptide/pharmacology , Glucagon/metabolism , Islets of Langerhans/metabolism , Peptide Fragments/pharmacology , Animals , Calcium Channels/drug effects , Calcium Channels/physiology , Exocytosis/drug effects , Glucagon-Like Peptide 1 , Glucagon-Like Peptides , Peptide Fragments/antagonists & inhibitors , Rats , Somatostatin/pharmacologyABSTRACT
In the insulin-secreting beta-cell line beta TC3, stimulation with 11.2 mmol/l glucose caused a rise in the intracellular free Ca2+ concentration ([Ca2+]i) in only 18% of the tested cells. The number of glucose-responsive cells increased after pretreatment of the cells with glucagon-like peptide I (GLP-I)(7-36)amide and at 10(-11) mol/l; 84% of the cells responded to glucose with a rise in [Ca2+]i. GLP-I(7-36)amide induces a rapid increase in [Ca2+]i only in cells exposed to elevated glucose concentrations (> or = 5.6 mmol/l). The action of GLP-I(7-36)amide and forskolin involved a 10-fold increase in cytoplasmic cAMP concentration and was mediated by activation of protein kinase A. It was not associated with an effect on the membrane potential but required some (small) initial entry of Ca2+ through voltage-dependent L-type Ca2+ channels, which then produced a further increase in [Ca2+]i by mobilization from intracellular stores. The latter effect reflected Ca(2+)-induced Ca2+ release and was blocked by ryanodine. Similar increases in [Ca2+]i were also observed in voltage-clamped cells, although there was neither activation of a background (Ca(2+)-permeable) inward current nor enhancement of the voltage-dependent L-type Ca2+ current. These observations are consistent with GLP-I(7-36) amide inducing glucose sensitivity by promoting mobilization of Ca2+ from intracellular stores. We propose that this novel action of GLP-I(7-36)amide represents an important factor contributing to its insulinotropic action.
Subject(s)
Calcium/metabolism , Glucose/pharmacology , Insulin/metabolism , Islets of Langerhans/metabolism , Peptide Fragments/pharmacology , Animals , Calcium Channels/drug effects , Calcium Channels/physiology , Cell Line , Colforsin/pharmacology , Cyclic AMP/metabolism , Cytoplasm/metabolism , Dose-Response Relationship, Drug , Glucagon , Glucagon-Like Peptide 1 , Glucagon-Like Peptides , Inositol Phosphates/metabolism , Insulin Secretion , Insulinoma , Islets of Langerhans/drug effects , Kinetics , Mice , Mice, Transgenic , Pancreatic Neoplasms , Ryanodine/pharmacology , Time Factors , Tumor Cells, CulturedABSTRACT
In mouse pancreatic beta-cells, extracellular ATP (0.1 mmol/l) effectively reduced glucose-induced insulin secretion. This inhibitory action resulted from a direct interference with the secretory machinery, and ATP suppressed depolarization-induced exocytosis by 60% as revealed by high-resolution capacitance measurements. Suppression of Ca2+-dependent exocytosis was mediated via binding to P2Y1 purinoceptors but was not associated with inhibition of the voltage-dependent Ca2+ currents or adenylate cyclase activity. Inhibition of exocytosis by ATP resulted from G-protein-dependent activation of the serine/threonine protein phosphatase calcineurin and was abolished by cyclosporin A and deltamethrin. In contrast to the direct inhibitory action on exocytosis, ATP reduced the whole-cell ATP-sensitive K+ (K(ATP)) current by 30% (via activation of cytosolic phospholipase A2), leading to membrane depolarization and stimulation of electrical activity. The stimulatory effect of ATP also involved mobilization of Ca2+ from thapsigargin-sensitive intracellular stores. We propose that the inhibitory action of ATP, by interacting with the secretory machinery at a level downstream to an elevation in [Ca2+]i, is important for autocrine regulation of insulin secretion in mouse beta-cells.
Subject(s)
Adenosine Triphosphate/analogs & derivatives , Adenosine Triphosphate/pharmacology , Insulin/metabolism , Islets of Langerhans/physiology , Receptors, Purinergic P2/physiology , Tolbutamide/pharmacology , Adenylate Cyclase Toxin , Animals , Calcium/metabolism , Cells, Cultured , Exocytosis/drug effects , Female , GTP-Binding Proteins/metabolism , Glucose/pharmacology , Guanosine Diphosphate/analogs & derivatives , Guanosine Diphosphate/pharmacology , Insecticides/pharmacology , Insulin Secretion , Islets of Langerhans/drug effects , Islets of Langerhans/metabolism , Kinetics , Membrane Potentials/drug effects , Membrane Potentials/physiology , Mice , Mice, Inbred Strains , Nitriles , Permethrin , Phospholipases A/metabolism , Phospholipases A2 , Pyrethrins/pharmacology , Receptors, Purinergic P2/drug effects , Receptors, Purinergic P2Y1 , Thionucleotides/pharmacology , Uridine Triphosphate/pharmacology , Virulence Factors, Bordetella/pharmacologyABSTRACT
The effect of glucagon-like peptide 1(7-36) amide [GLP-1(7-36) amide] on membrane potential, whole-cell ATP-sensitive potassium channel (K[ATP]) and Ca2+ currents, cytoplasmic Ca2+ concentration, and exocytosis was explored in single human beta-cells. GLP-1(7-36) amide induced membrane depolarization that was associated with inhibition of whole-cell K(ATP) current. In addition, GLP-1(7-36) amide (and forskolin) produced greater than fourfold potentiation of Ca2+-dependent exocytosis. The latter effect resulted in part (40%) from acceleration of Ca2+ influx through voltage-dependent (L-type) Ca2+ channels. More importantly, GLP-1(7-36) amide (via generation of cyclic AMP and activation of protein kinase A) potentiated exocytosis at a site distal to a rise in the cytoplasmic Ca2+ concentration. Photorelease of caged cAMP produced a two- to threefold potentiation of exocytosis when the cytoplasmic Ca2+ concentrations were clamped at > or =170 nmol/l. The effect of GLP-1(7-36) amide was antagonized by the islet hormone somatostatin. Similar effects on membrane potential, ion conductances, and exocytosis were observed with glucose-dependent insulinotropic polypeptide (GIP), the second major incretin. The present data suggest that the strong insulinotropic action of GLP-1(7-36) amide and GIP in humans results from its interaction with several proximal as well as distal important regulatory steps in the stimulus-secretion coupling.
Subject(s)
Exocytosis/drug effects , Islets of Langerhans/cytology , Neurotransmitter Agents/pharmacology , Peptide Fragments/pharmacology , Adult , Calcium/analysis , Calcium/metabolism , Calcium Channels/drug effects , Calcium Channels/physiology , Cells, Cultured , Colforsin/pharmacology , Cyclic AMP/metabolism , Cyclic AMP/physiology , Cyclic AMP-Dependent Protein Kinases/physiology , Exocytosis/physiology , Female , Gastric Inhibitory Polypeptide/pharmacology , Glucagon , Glucagon-Like Peptide 1 , Glucagon-Like Peptides , Humans , Islets of Langerhans/drug effects , Islets of Langerhans/physiology , Male , Membrane Potentials/drug effects , Membrane Potentials/physiology , Middle Aged , Potassium Channels/drug effects , Potassium Channels/physiology , Somatostatin/pharmacologyABSTRACT
We have monitored electrical activity, voltage-gated Ca2+ currents, and exocytosis in single rat glucagon-secreting pancreatic A-cells. The A-cells were electrically excitable and generated spontaneous Na+- and Ca2+-dependent action potentials. Under basal conditions, exocytosis was tightly linked to Ca2+ influx through omega-conotoxin-GVIA-sensitive (N-type) Ca2+ channels. Stimulation of the A-cells with adrenaline (via beta-adrenergic receptors) or forskolin produced a greater than fourfold PKA-dependent potentiation of depolarization-evoked exocytosis. This enhancement of exocytosis was due to a 50% enhancement of Ca2+ influx through L-type Ca2+ channels, an effect that accounted for <30% of the total stimulatory action. The remaining 70% of the stimulation was attributable to an acceleration of granule mobilization resulting in a fivefold increase in the number of readily releasable granules near the L-type Ca2+ channels.
Subject(s)
Calcium Channels/metabolism , Calcium/physiology , Epinephrine/pharmacology , Glucagon/metabolism , Islets of Langerhans/metabolism , Islets of Langerhans/physiology , Animals , Cyclic AMP/pharmacology , Cyclic AMP-Dependent Protein Kinases/metabolism , Cytoplasm/metabolism , Electric Conductivity , Enzyme Activation , Exocytosis/drug effects , Exocytosis/physiology , Glucose/metabolism , Islets of Langerhans/drug effects , Male , Osmolar Concentration , Rats , Rats, Inbred Lew , Receptors, Adrenergic, beta/physiologyABSTRACT
The correlation between acetylcholine induced changes in the intracellular free, Ca2+ concentration ([Ca2+]i), and the inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) content in isolated acini from the rat parotid and lacrimal glands was investigated. Applying digital image processing on Fura-2 loaded acini, we observed that Ca2+ increases either simultaneously throughout the acinar configurations or that occasionally, the rise near the lumen can precede the rise near the basal part by 50-100 ms. Measurements on cell suspensions revealed a correlation between changes in [Ca2+]i and changes in the cellular Ins(1,4,5)P3 content, and it is concluded that in the individual cells Ins(1,4,5)P3 is released to the cytosol within the first second after stimulation. Applying a diffusion coefficient for cytoplasmic Ins(1,4,5)P3 of 2.83 x 10(-6) cm2/s (Allbritton et al., 1992, Science, 258, 1812-1815), we have calculated the concentration profile for this messenger in a sphere with a radius of 10 microns where Ins(1,4,5)P3 is released in the center following a monoexponential function with a rate constant of 4 s-1. Assuming that Ins(1,4,5)P3 concentrations of 1 or 5% of the maximum value is able to release Ca2+, we calculated that Ca2+ waves can appear at a rate of 100 or 40 microns/s. The present data are consistent with Ins(1,4,5)P3 being a cellular messenger, that by diffusion, initiates the Ca2+ release from the cellular pools within the first fraction of a second.
Subject(s)
Calcium/physiology , Inositol 1,4,5-Trisphosphate/physiology , Lacrimal Apparatus/physiology , Pancreas/physiology , Signal Transduction/physiology , Acetylcholine/pharmacology , Animals , Body Water/metabolism , Cell Communication , Cell Compartmentation , Diffusion , Inositol Phosphates/biosynthesis , Lacrimal Apparatus/drug effects , Male , Pancreas/drug effects , Rats , Rats, Wistar , Sodium/metabolismABSTRACT
In the present study, we describe a role for cyclic GMP (cGMP) in the signalling pathway that leads from alpha-adrenergic receptor activation to intracellular Ca2+ mobilization in rat lacrimal acinar cells. The alpha-adrenergic agonist, phenylephrine, stimulates intracellular Ca2+ release which is blocked by inhibitors of guanylate cyclase and cGMP-dependent protein kinase Ia. The membrane-permeable cGMP analogues, dibutyryl-cGMP and 8-bromo-cGMP, potentiate ( approximately 5-fold) the Ca2+ response to submaximal phenylephrine stimulation. In contrast, the same cGMP analogues have no effect on cyclic ADP-ribose-evoked Ca2+ release from permeabilized lacrimal acinar cells. Collectively, these findings suggest that cGMP, via cGMP-dependent protein kinase I alpha , is required for intracellular Ca2+ release following alpha-adrenergic receptor activation in lacrimal acinar cells.
Subject(s)
Adenosine Diphosphate Ribose/analogs & derivatives , Calcium/metabolism , Cyclic GMP/analogs & derivatives , Cyclic GMP/pharmacology , Lacrimal Apparatus/metabolism , Phenylephrine/pharmacology , Acetylcholine/pharmacology , Adenosine Diphosphate Ribose/pharmacology , Aminoquinolines/pharmacology , Animals , Arginine/analogs & derivatives , Arginine/pharmacology , Cells, Cultured , Cyclic ADP-Ribose , Cyclic GMP/metabolism , Dibutyryl Cyclic GMP/pharmacology , Enzyme Inhibitors/pharmacology , Guanylate Cyclase/antagonists & inhibitors , Kinetics , Lacrimal Apparatus/cytology , Lacrimal Apparatus/drug effects , Male , Nitric Oxide Synthase/antagonists & inhibitors , Nitroarginine , Rats , Rats, WistarABSTRACT
In permeabilized lacrimal acinar cells, cyclic ADP-ribose (cADP-ribose) and inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) release Ca2+ in a dose dependent manner from distinct thapsigargin-sensitive Ca2+ pools. Ryanodine specifically blocks the Ca2+ response to cADP-ribose, whereas heparin strongly reduces the response to Ins(1,4,5)P3 application. GTP causes a rapid Ca2+ release by a ryanodine- and heparin-insensitive mechanism and potentiates Ins(1,4,5)P3 but not cADP-ribose evoked Ca2+ release. It is estimated that cADP-ribose can release 16 mumol Ca2+/l cells, whereas Ins(1,4,5)P3 can mobilize 55 mumol Ca2+/l cells. The results suggest that cADP-ribose and Ins(1,4,5)P3 release Ca2+ from distinct internal stores and that a third Ca2+ pool exists which can selectively interact with the Ins(1,4,5)P3-sensitive Ca2+ store by a GTP-mediated process.
Subject(s)
Adenosine Diphosphate Ribose/analogs & derivatives , Calcium/metabolism , Calcium/pharmacology , Lacrimal Apparatus/drug effects , Adenosine Diphosphate Ribose/pharmacology , Animals , Cell Compartmentation , Cell Membrane Permeability , Cyclic ADP-Ribose , Cytoplasm/metabolism , Guanosine Triphosphate/pharmacology , Heparin/pharmacology , In Vitro Techniques , Rats , Ryanodine/pharmacology , Terpenes/pharmacology , ThapsigarginABSTRACT
The signal transduction pathway of the cloned human glucagon-like peptide-1 (GLP-1) receptor was studied in voltage-clamped Xenopus oocytes. Binding of GLP-1(7-36)amide was associated with cAMP production, increased [Ca2+]i and activation of Ca2+-dependent Cl- current. The effect of GLP-1(7-36)amide reflects intracellular Ca2+ mobilization and was suppressed by injection of the Ca2+ chelator BAPTA and the inositol trisphosphate receptor antagonist heparin. The responses were not mimicked by the adenylate cyclase activator forskolin and unaffected by the protein kinase A (PKA) inhibitor Rp-cAMPS. We conclude that GLP-1 receptor expression in Xenopus oocytes evokes inositol trisphosphate-dependent intracellular Ca2+ mobilization independent of the cAMP/PKA signaling pathway.
Subject(s)
Calcium/metabolism , Inositol 1,4,5-Trisphosphate/metabolism , Receptors, Glucagon/metabolism , Adenylyl Cyclases/metabolism , Animals , Chloride Channels/physiology , Cyclic AMP-Dependent Protein Kinases/metabolism , Gene Expression , Glucagon-Like Peptide-1 Receptor , Humans , Intracellular Fluid , Oocytes/metabolism , Receptors, Glucagon/genetics , Xenopus laevis/metabolismABSTRACT
The actions of glucagon-like peptide-1(7-36)amide (GLP-1(7-36)amide) on cellular signalling were studied in human embryonal kidney 293 (HEK 293) cells stably transfected with the cloned human GLP-1 receptor. The cloned GLP-1 receptor showed a single high-affinity binding site (Kd = 0.76 nM). Binding of GLP-1(7-36)amide stimulated cAMP production in a dose-dependent manner (EC50 = 0.015 nM) and caused an increase in the intracellular free Ca2+ concentration ([Ca2+]i). The latter effect reflected Ca(2+)-induced Ca2+ release and was suppressed by ryanodine. We propose that the ability of GLP-1(7-36)amide to increase [Ca2+]i results from sensitization of the ryanodine receptors by a protein kinase A dependent mechanism.
Subject(s)
Calcium/metabolism , Cyclic AMP/metabolism , Receptors, Glucagon/physiology , Acetylcholine/pharmacology , Calcium/pharmacology , Calcium Channel Blockers/pharmacology , Cell Line , Cloning, Molecular , Cyclic AMP/analogs & derivatives , Cyclic AMP/pharmacology , Embryo, Mammalian , Glucagon/pharmacology , Glucagon-Like Peptide 1 , Glucagon-Like Peptide-1 Receptor , Glucagon-Like Peptides , Humans , Ionomycin/pharmacology , Kidney , Peptide Fragments/pharmacology , Receptors, Glucagon/biosynthesis , Receptors, Glucagon/drug effects , Recombinant Proteins/biosynthesis , Recombinant Proteins/drug effects , Recombinant Proteins/metabolism , Ryanodine/pharmacology , Thionucleotides/pharmacologyABSTRACT
1. The cellular processes involved in the desensitization of the glucagon-like peptide 1 receptors were investigated by measurements of the glucagon-like peptide 1(7-36)amide (GLP-1(7-36)amide)-induced increases in intracellular free Ca2+ concentration ([Ca2+]i) in insulin-secreting beta TC3 cells. 2. In the presence of 11.2 mM glucose, stimulation with GLP-1(7-36)amide led to a small membrane depolarization (< 10 mV), induction of electrical activity and a rapid increase in [Ca2+]i. The increase in [Ca2+]i was not observed in the presence of the L-type Ca(2+)-channel antagonist nifedipine. However, nifedipine was ineffective when applied after addition of GLP-1(7-36)amide. 3. The increase in [Ca2+]i evoked by GLP-1-(7-36)amide was transient and even in the continued presence of the agonist, [Ca2+]i returned to the basal value within 4-5 min. The latter process was slowed, but not prevented, by inhibition of protein kinase C (PKC) by staurosporine and Ro31-8220. 4. Short pretreatment of the cells with the phorbol ester, 4-beta-phorbol-12-beta-myristate-13-alpha-acetate (PMA), an activator of PKC, reduced the GLP-1(7-36)amide-evoked increase in [Ca2+]i by 75%. This effect of PMA was fully reversed by staurosporine and Ro31-8220. 5. The ability of GLP-1(7-36)amide to increase [Ca2+]i disappeared upon pre-exposure of the cells to the hormone (desensitization). This process was maximal within 5 min of exposure to the agonist. Following removal of the agonist from the medium, the ability to respond to subsequent stimulation by GLP-1(7-36)amide recovered gradually with time; half and complete recovery requiring > 20 min and 60 min, respectively. The desensitizing action of GLP-1(7-36)amide persisted in the presence of either staurosporine or forskolin and did not require an elevation of [Ca2+]i. 6. Our data suggest that the GLP-1(7-36)amide-evoked increase in [Ca2+]i is initiated by Ca(2+)-influx though voltage-dependent and nifedipine-sensitive L-type Ca2+ channels but depends principally on Ca2+ mobilization from internal stores for its maintenance. The desensitization of the GLP-1 receptors that occurs in the continued presence of the agonist does not result from the activation of protein kinase A or Ca(2+)-dependent kinases/phosphatases. Our data indicate that activation of PKC may contribute to the desensitization of the GLP-1 receptors but that other (PKC-independent) mechanisms also participate in this process.
Subject(s)
Calcium/metabolism , Glucagon/pharmacology , Insulinoma/metabolism , Protein Kinase C/drug effects , Receptors, Glucagon/physiology , Animals , Glucose/pharmacology , Mice , Mice, Inbred Strains , Time Factors , Tumor Cells, CulturedABSTRACT
The effect of the imidazoline compound LY374284 has been studied in pancreatic islets of db/db mice, a progressive model of diabetes. In perifusion experiments, pancreatic islets of db/db mice showed a progressive deterioration of glucose-induced insulin release with increasing age, whereby the first phase of insulin secretion was almost completely abolished and the second phase was substantially decreased by 15 weeks of age. LY374284 restored the first phase of glucose-induced insulin secretion in islets of 16-week-old db/db mice to 70% of that observed in islets isolated from age-matched nondiabetic db/1 mice. LY374284 did not affect insulin secretion at a low glucose concentration (3.3 mmol/L). A similar restoration of first phase insulin secretion was observed after application of glucagon-like peptide-1, whereas a sulfonylurea agent, tolbutamide, was inactive. LY374284 did not affect cytosolic Ca(2+) concentration or cellular ATP content. Furthermore, LY374284 strongly enhanced insulin secretion in islets of db/db and db/1 mice maximally depolarized by 30 mmol/L K(+) and 250 micromol/L diazoxide. The present data suggest that the imidazoline compound LY374284 restores biphasic insulin secretion in islets of diabetic db/db mice by amplifying glucose-induced insulin secretion at a site distal to Ca(2+)-influx.
Subject(s)
Diabetes Mellitus/metabolism , Imidazoles/pharmacology , Insulin/metabolism , Islets of Langerhans/metabolism , Adenosine Triphosphate/metabolism , Animals , Calcium/metabolism , Culture Techniques , Disease Models, Animal , Glucose/metabolism , Humans , Imidazoles/chemistry , Insulin Secretion , Islets of Langerhans/drug effects , Male , Membrane Potentials/physiology , Mice , Mice, Inbred C57BLABSTRACT
Using capacitance measurements, we have explored the effects of three different scinderin actin-binding peptides (Sc(77-89); Sc(138-146); Sc(511-523)) on Ca(2+)- and GTPgammaS-induced exocytosis in single mouse pancreatic beta-cells. Sc(77-89) (10 microM) reduced exocytosis by 43% in whole-cell experiments in which secretion was triggered by intracellular dialysis with a Ca(2+)-EGTA buffer with a free Ca(2+) concentration of 2 microM. A more pronounced reduction of the rate of exocytosis was observed with Sc(138-146) (72%) but not with Sc(511-523) (39%). Sc(138-146) also reduced depolarisation-induced exocytosis by 61% without affecting the whole-cell Ca(2+) current. When exocytosis was triggered by infusion of GTPgammaS, all scinderin-binding peptides reduced exocytosis by 59-75%. These data suggest that scinderin might be important for controlling cortical actin network dynamics in mouse pancreatic beta-cells and that scinderin-induced cortical filamentous actin disassembly is required for insulin secretion.
Subject(s)
Calcium/antagonists & inhibitors , Exocytosis/drug effects , Guanosine 5'-O-(3-Thiotriphosphate)/antagonists & inhibitors , Islets of Langerhans/drug effects , Microfilament Proteins/pharmacology , Animals , Cells, Cultured , Gelsolin , Insulin/metabolism , Insulin Secretion , Mice , Microfilament Proteins/chemistry , Patch-Clamp TechniquesABSTRACT
The effects of the two prandial glucose regulators, repaglinide and nateglinide, on ATP-sensitive K(+) (K(ATP)) channel activity, membrane potential and exocytosis in single rat pancreatic A-cells were investigated using the patch-clamp technique. K(ATP) channel activity was reversibly blocked by repaglinide (K(d)=22 nM) and nateglinide (K(d)=410 nM) and this was associated with membrane depolarisation and initiation of electrical activity. The effect of repaglinide and nateglinide on stimulation of glucagon secretion by direct interference with the exocytotic machinery was investigated by the use of capacitance measurements. Nateglinide, but not repaglinide, at concentrations similar to those required to block K(ATP) channels potentiated Ca(2+)-evoked exocytosis 3-fold. In alphaTC1-9 glucagonoma cells addition of nateglinide, but not repaglinide, was associated with stimulation of glucagon secretion. These results indicate that the fast-acting insulin secretagogue nateglinide is glucagonotropic primarily by stimulating Ca(2+)-dependent exocytosis.